Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 1 | Russia | 14 Jun 2023 | |
Rheumatoid Arthritis | Phase 1 | Russia | 14 Jun 2023 |